Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca invests $2B in Summit Therapeutics, gaining 12% equity stake and oncology co-development alliance
Equity investment, oncology, antibody, co-development, milestone payments - Read more

Novo, Hengrui Pharma partner on weekly oral GLP-1R/GIPR dual agonist for obesity, $300M upfront, up to $2.6B
Licensing deal, obesity, small molecule, milestone payments, royalties - Read more

Ginkgo Bioworks, Apheris, AbbVie, argenx, Lundbeck, Takeda launch Antibody Developability Consortium to build industry's largest standardized dataset
Research collaboration, antibody, AI/ML, drug discovery, manufacturability - Read more

DrugBank collaborates with Microsoft to integrate biopharma knowledge graph into Copilot ecosystem
Research collaboration, AI/ML, drug discovery, data analytics, R&D - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

AC Immune's (ACI-7104) meets all Ph2 primary endpoints, shows 100% immunogenicity in early-stage Parkinson's disease
Vaccine, neurological, active immunotherapy, Parkinson's disease, alpha-synuclein - Read more

Eccogene receives $50M milestone from AstraZeneca as oral GLP-1 elecoglipron enters global Phase 3 trials for cardiometabolic diseases
Small molecule, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes, heart failure - Read more

ai3Bio emerges from stealth with $48M to develop AI-driven platform targeting diseased Th17 cells in autoimmune diseases
Autoimmune, AI/ML platform, cell therapy, mRNA, lipid nanoparticle, platform-enabled - Read more

Precision Neuroscience raises $250M Series D for brain-computer interface expansion, commercialization
Brain-computer interface, neurological, medical devices, clinical-stage - Read more

Breye Therapeutics raises €67.5M ($76.5M) Series A to fund Phase II diabetic retinopathy study
Ophthalmology, small molecule, diabetic retinopathy, clinical-stage, rare disease - Read more

Aptadir Therapeutics closes €40M ($45M) seed round to advance RNA therapeutics pipeline
RNA therapeutics, rare disease, Fragile X syndrome, platform technology, epigenetics, preclinical - Read more

Genentech breaks ground on $750M Hillsboro, Oregon manufacturing expansion, doubling facility size by 2031
Fill-finish manufacturing, oncology, neurology, immunology, operational, major transaction - Read more

Roche plans autonomous AI labs for drug R&D, targeting faster clinical candidate development
AI-driven drug discovery, drug development, operational, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

uniQure's AMT-130 (ifezuntirgene inilparvovec) Ph1/2 shows reduced disease slowing at 4 years in Huntington's disease
Gene therapy, neurological, Huntington's disease, AAV vector, huntingtin protein - Read more

BioNTech closes 3 German sites, cutting 1,800 jobs after failed buyer search
mRNA vaccine, oncology, cost reduction, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here